ORAGENICS INC — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
On August 26, 2026, Oragenics received a NYSE American deficiency letter for failing continued listing standards (stockholders' equity requirement: $4M if three of four years reported losses, or $6M if five consecutive years reported losses). The company has 45 days to submit a compliance plan and until February 25, 2028 to regain compliance. Operationally, the company has dosed 9 participants in its Australia-based Phase IIa trial of ONP-002 for mTBI across three active sites and expects to submit a U.S. IND application by end of 2026.
Why this rating
Delisting threat is business-critical for $3.1M market-cap company. Reputational and operational damage from exchange removal could impair financing, partnerships, and clinical recruitment—existential risk. Clinical progress is modest and expected; regulatory momentum is offset by listing jeopardy.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.52 ▼ 0.02% | at our read · backfill $0.52 | +10 min · backfill $0.52 ▼ 0.02% | +30 min · backfill $0.52 ▲ 0.00% |
The stock had already moved +0.02% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.